GDC-0810 (ARN-810): A Novel Oral SERD for ER+ Breast Cancer Treatment
Exploring the efficacy and mechanism of a promising new therapy for estrogen receptor-positive breast cancer.
Get a Quote & SampleProduct Core Value
GDC-0810 (ARN-810)
GDC-0810 (ARN-810) is a groundbreaking Selective Estrogen Receptor Downregulator (SERD) offering a new avenue for treating estrogen receptor-positive (ER+) breast cancer. Its unique mechanism involves degrading the estrogen receptor, making it effective even in cases of resistance to existing therapies and in the presence of specific ERα mutations. This advanced compound is designed for oral administration, enhancing patient convenience.
- Discover the potent anti-tumor activity of GDC-0810 against tamoxifen-resistant breast cancer models, showcasing its potential to overcome established resistance mechanisms.
- Understand the selective estrogen receptor degrader mechanism of action, highlighting how GDC-0810 targets ERα degradation for therapeutic benefit.
- Learn about ARN-810's role as an oral SERD for ER+ breast cancer treatment, offering a more convenient administration route compared to injectable therapies.
- Explore the ongoing GDC-0810 clinical trials for breast cancer, indicating promising progress towards wider clinical application.
Key Advantages Offered
Oral Bioavailability
GDC-0810's oral bioavailability represents a significant advantage, improving patient convenience and adherence in ER+ breast cancer treatment.
Overcoming Resistance
The effectiveness of GDC-0810 against tamoxifen-resistant breast cancer models demonstrates its ability to tackle complex disease states.
Targeting ER Mutations
GDC-0810's efficacy in models with ERα mutations highlights its potential to address a critical challenge in advanced ER+ breast cancer.
Key Applications
Pharmaceutical Research
Serving as a crucial compound in scientific research, facilitating a deeper understanding of estrogen receptor signaling pathways and resistance mechanisms in breast cancer.
Drug Development
Acting as a lead compound in the development of next-generation targeted therapies for estrogen receptor-positive breast cancer.
Oncology Treatment Strategies
Providing a novel therapeutic option for patients with advanced or metastatic ER+ breast cancer, especially those who have developed resistance to standard treatments.
Biomedical Studies
Utilized in various biomedical studies to investigate the complex interactions within hormone-driven cancers and to explore new treatment modalities.